Glooko study reports lower blood glucose, eA1C levels with mobile management app use
Glooko presented data from 2 retrospective studies of its diabetes management mobile application, touting drops in average blood glucose, estimated A1C levels and hyperglycemia rates in users.
Results from the study indicated a number of improvements for patients using the application, including an increase in the rate of blood glucose testing. The company said that patients in the trial were shown to be, on average, already maintaining their diabetes adequately with eA1C levels below 8%.
“We are thrilled to see this additional clinical evidence that shows the positive impact Glooko can have on people with diabetes. Glooko’s mission has always been to improve the clinical outcomes for people with diabetes by making diabetes management easier through digital tools. Our user satisfaction rates coupled with this clinical evidence adds credence to the investments that digital health companies have been making to improve the lives of people with chronic diseases,” CEO Rick Altinger said in a prepared statement.
Data from the trial indicated that at 2 months, Glooko users showed a 3.5% drop in average blood glucose, with eA1C dropping between 0.3% and 0.5%. The rate of hyperglycemic events dropped by 4.38% per month over 2 months, while blood glucose test rates rose to between 16.3% and 34.2%.